Peregrine Pharmaceuticals to Present at Biotech Showcase 2018
January 02 2018 - 8:05AM
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a
company committed to improving patient lives by manufacturing and
delivering high quality biologics, today announced that its
president and chief executive officer, Roger J. Lias, Ph.D., will
deliver a corporate presentation at the 10th Annual Biotech
Showcase™, being held January 8-10, 2018 at the Hilton San
Francisco Union Square in San Francisco.
Details of this presentation are as follows:
- Biotech Showcase 2018Time/Date: 3:30 p.m. PT on Monday, January
8, 2018Location: Hilton San Francisco Union SquareRoom: Yosemite –
B (Ballroom Level)
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a company
transitioning from an R&D focused business to a pure play
contract development and manufacturing organization (CDMO).
Peregrine's in-house CDMO services, including cGMP manufacturing
and development capabilities, are provided through its wholly-owned
subsidiary Avid Bioservices, Inc. (www.avidbio.com).
Peregrine is pursuing the licensing or sale of
its proprietary R&D assets, including its lead immunotherapy
candidate, bavituximab, which is currently being evaluated in
clinical trials in combination with immune stimulating therapies
for the treatment of various cancers. For more information,
please visit www.peregrineinc.com.
About Avid Bioservices,
Inc. Avid Bioservices, a wholly owned subsidiary
of Peregrine Pharmaceuticals, provides a comprehensive range
of process development, high quality cGMP clinical and commercial
manufacturing services for the biotechnology and biopharmaceutical
industries. With nearly 25 years of experience producing
monoclonal antibodies and recombinant proteins in batch, fed-batch
and perfusion modes, Avid's services include cGMP clinical and
commercial product manufacturing, purification, bulk packaging,
stability testing and regulatory strategy, submission and
support. The company also provides a variety of process
development activities, including cell line development and
optimization, cell culture and feed optimization, analytical
methods development and product characterization. For more
information about Avid, please visit www.avidbio.com.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024